Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B‐cell lymphoma treated with the R‐<scp>CHOP</scp> regimen

A discovery study was carried out where serum samples from 22 systemic lupus erythematosus (SLE) patients and matched healthy controls were hybridized to antibody-coated glass slide arrays that interrogated the level of 274 human proteins. On the basis of these screens, 48 proteins were selected for ELISA-based validation in an independent cohort of 28 SLE patients. Whereas AXL, ferritin, and sTNFRII were significantly elevated in patients with active lupus nephritis (LN) relative to SLE patients who were quiescent, other molecules such as OPN, sTNFRI, sTNFRII, IGFBP2, SIGLEC5, FAS, and MMP10 exhibited the capacity to distinguish SLE from healthy controls with ROC AUC exceeding 90%, all with p < 0.001 significance. These serum markers were next tested in a cohort of 45 LN patients, where serum was obtained at the time of renal biopsy. In these patients, sTNFRII exhibited the strongest correlation with eGFR (r = −0.50, p = 0.0014) and serum creatinine (r = 0.57, p = 0.0001), although AXL, FAS, and IGFBP2 also correlated with these clinical measures of renal function. When concurrent renal biopsies from these patients were examined, serum FAS, IGFBP2, and TNFRII showed significant positive correlations with renal pathology activity index, while sTNFRII displayed the highest correlation with concurrently scored renal pathology chronicity index (r = 0.57, p = 0.001). Finally, in a longitudinal cohort of seven SLE patients examined at ∼3 month intervals, AXL, ICAM-1, IGFBP2, SIGLEC5, sTNFRII, and VCAM-1 demonstrated the ability to track with concurrent disease flare, with significant subject to subject variation. In summary, serum proteins have the capacity to identify patients with active nephritis, flares, and renal pathology activity or chronicity changes, although larger longitudinal cohort studies are warranted.

show abstract

“…40 In cancer, serum sTNFRII is associated with the outcome of patients with diffuse large B-cell lymphoma treated with the R-CHOP regimen. 58 …”

Section: Discussionmentioning

confidence: 99%

Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study

Ding

Han

et al. 2016

J. Proteome Res.

View full text Add to dashboard Cite

show abstract

“…In recent years, sTNFR2 has been suggested as a candidate biomarker in several conditions, e.g. specific types of heart failure [291], multiple sclerosis [292] and B cell lymphoma [293].…”

Section: The Role Of Tnfr2 In Lnmentioning

confidence: 99%

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus

Parodis

Sjöwall

Jönsen

et al. 2017

Autoimmunity Reviews

View full text Add to dashboard Cite

“…The roles of TNFR2 in prognosis have been reported by several researchers, but the results were inconsistent. Heemann C and Nakamura N reported that the circulating level of TNFR2 was associated with poor outcome of patients with peripheral T-cell non-Hodgkin lymphoma and diffuse large B-cell lymphoma ( 26 , 27 ). However, in 2005, Mestiri S reported that the 196R-TNFRII allele revealed a significant association with increased OS and disease-free survival in breast carcinoma patients ( 28 ).…”

Section: Discussionmentioning

confidence: 99%

Clinical significance of tumor necrosis factor receptor 2 in middle and lower thoracic esophageal squamous cell carcinoma

Yang

Wang

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

High expression and role of tumor necrosis factor receptor 2 (TNFR2) in cancer progression and prognosis has been reported in several types of tumors. However, its role in esophageal carcinoma (EC) remains unknown. In the present study, TNFR2 expression in middle and lower thoracic esophageal squamous cell carcinoma (ESCC) was detected using immunohistochemistry (IHC). Chi-square test revealed that TNFR2 was positively correlated with invasion depth, advanced clinical stage and low differentiation degree. Furthermore, survival analysis revealed that TNFR2 was positively correlated with poor overall survival (OS). Moreover, univariate COX regression analysis revealed that clinical stage, lymph node involvement, and invasion depth can affect the OS of ESCC patients, while multivariate COX regression analysis revealed that lymph node involvement and invasion depth can affect the OS of ESCC patients. In middle thoracic ESCC patients, TNFR2 was positively correlated with invasion depth, advanced clinical stage and poor OS. Furthermore, univariate and multivariate COX regression analysis both revealed that clinical stage, lymph node involvement, and invasion depth can affect OS. In lower thoracic ESCC patients, TNFR2 was positively correlated with low differentiation degree. Furthermore, the positive correlation of TNFR2 with poor OS did not reach statistical significance. In addition, univariate COX regression analysis revealed that only lymph node involvement could affect OS. All the results suggest that TNFR2 can play an important role in the progression and poor prognosis of ESCC patients. Moreover, the role of TNFR2 in the prognosis of middle thoracic ESCC patients was earlier and stronger than in lower thoracic ESCC patients.

show abstract

Serum level of soluble tumor necrosis factor receptor 2 is associated with the outcome of patients with diffuse large B‐cell lymphoma treated with the R‐CHOP regimen

Abstract: Serum sTNFR2 might be a powerful prognostic factor for patients with DLBCL in the rituximab era.

Cited by 15 publications

References 34 publications

Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study

Antibody-Array-Based Proteomic Screening of Serum Markers in Systemic Lupus Erythematosus: A Discovery Study

Smoking and pre-existing organ damage reduce the efficacy of belimumab in systemic lupus erythematosus

Clinical significance of tumor necrosis factor receptor 2 in middle and lower thoracic esophageal squamous cell carcinoma

Contact Info

Product

Resources

About